Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 216 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Results available

Beta-blockade Effects on Memory for Cocaine Craving

NCT00830362
Conditions
Cocaine Dependence
Interventions
Propranolol, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis in YMSM

NCT01033942
Conditions
HIV
Interventions
coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP, Placebo, Many Men, Many Voices (3MV)
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 22 Years · Male only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Chicago, Illinois
Not listed Not applicable Interventional Accepts healthy volunteers

D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights

NCT01037101
Conditions
Height Phobia
Interventions
In Vivo Exposure Therapy, Virtual Reality Exposure Therapy, D-Cycloserine, Placebo
Behavioral · Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Charleston, West Virginia
Completed Phase 2 Interventional Accepts healthy volunteers

Anthrax AV7909 Boost Evaluation Study

NCT05997264
Conditions
Anthrax
Interventions
AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more
Conditions
Social Anxiety Disorder
Interventions
Seromycin, Virtual Reality Exposure Therapy, Placebo
Drug · Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Claustrophobia, Obsessive-Compulsive Disorder, Arachnophobia
Interventions
Experimental Scent, Control Scent, No-Scent Control, In-Vivo Exposure
Other · Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Conditions
PTSD
Interventions
Virtual reality exposure therapy, 0.5 mg DEX
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Ulcerative Colitis
Interventions
Etrozulimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more
Conditions
PTSD
Interventions
Prolonged Exposure therapy, Hydrocortisone
Behavioral · Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Multiple Sclerosis
Interventions
Phototherapy
Device
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Urbana, Illinois
Not listed Not applicable Interventional Accepts healthy volunteers

A Randomized Clinical Trial of Hydrocortisone Augmentation of Prolonged Exposure

NCT01525680
Conditions
Post Traumatic Stress Disorder
Interventions
Hydrocortisone augmented Prolonged Exposure Therapy, Prolonged exposure therapy with placebo administration
Other
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Marburg Hemorrhagic Fever
Interventions
AVI-6003, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Cypress, California
Conditions
Tobacco Use Disorder
Interventions
ModafinilNicotine Replacement Therapy, Modafinil
Drug
Lead sponsor
Catherine Martin, MD
Other
Eligibility
16 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Obsessive-compulsive Disorder
Interventions
Cognitive-behavioral therapy, d-cycloserine, Pill placebo
Behavioral · Drug
Lead sponsor
University of South Florida
Other
Eligibility
7 Years to 17 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
2
States / cities
St. Petersburg, Florida • Cambridge, Massachusetts
Conditions
Lyme Disease
Interventions
TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose, Placebo
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
722 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
19
States / cities
Pikesville, Maryland • Brookline, Massachusetts • Fall River, Massachusetts + 16 more
Conditions
Myocardial Ischemia, Critical Illness, Endothelial Dysfunction
Interventions
Day Light, Placebo light, ICU Intense Light, ICU Placebo light
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Completed Phase 3 Interventional Accepts healthy volunteers

Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling

NCT00221975
Conditions
Bipolar Disorder
Interventions
Divalproex, Lamotrigine, Lithium
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
16 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine

NCT01944423
Conditions
Nicotine Addiction, Panic Attack
Interventions
d-cycloserine, Pill Placebo, Nicotine replacement therapy, Panic and Smoking Reduction Treatment
Drug · Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Austin, Texas
Conditions
Experimental, Placebo Contol
Interventions
Cognitive Anxiety Sensitivity Treatment, Physical Health Education Training
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Tallahassee, Florida
Recruiting Not applicable Interventional Accepts healthy volunteers

Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation

NCT05802680
Conditions
Attention Deficit Hyperactivity Disorder, Attention Difficulties, Attention Deficit, Cognitive Deficit, Wellness
Interventions
Transcranial photobiomodulation, Sham transcranial photobiomodulation
Device
Lead sponsor
Francisco Gonzalez-Lima, PhD
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Austin, Texas
Conditions
Panic Disorder
Interventions
Cognitive behavioral therapy, D-cycloserine
Behavioral · Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Hartford, Connecticut • Boston, Massachusetts
Conditions
Obstetric Labour, Premature
Interventions
Retosiban, Atosiban, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Weeks to 20 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Park Ridge, Illinois • Galveston, Texas
Conditions
Peripheral Neuropathy, Pain, Neuropathic, Diabetes
Interventions
Moxibustion - Traditional (Active), Moxibustion - Smokeless - (Active), Placebo Moxibustion
Other
Lead sponsor
New York University
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)

NCT04774250
Conditions
Hearing Loss, Noise-Induced
Interventions
Zonisamide 100Mg Cap, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Akron, Ohio